AX 208

Drug Profile

AX 208

Alternative Names: AX208

Latest Information Update: 19 Mar 2009

Price : $50

At a glance

  • Originator SYGNIS Bioscience GmbH
  • Class Amino acids; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma; Huntington's disease; Parkinson's disease

Most Recent Events

  • 30 Apr 2007 Preclinical trials in Glaucoma in Germany (unspecified route)
  • 30 Apr 2007 Preclinical trials in Parkinson's disease in Germany (unspecified route)
  • 30 Apr 2007 Preclinical trials in Huntington's disease in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top